Description: Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
Home Page: www.ascletis.com
Building D
Hangzhou,
China
Phone:
86 571 8538 9730
Officers
| Name | Title |
|---|---|
| Dr. Jinzi Jason Wu | Founder, Chairman & CEO |
| Dr. Handan He Ph.D. | Chief Scientific Officer |
| Ms. Hejingdao Wu | Sr. VP of Operations & Exec. Director |
| Ms. Yuemei Yan | Sr. VP of Clinical Devel. Operations |
| Dr. Kristjan Sigurdur Gudmundsson | Sr. Consultant & Head of Discovery |
| Dr. George Zhengzhi Hill | Sr. Consultant & Chief Medical Advisor |
| Mr. John P. Gargiulo M.B.A. | Chief Bus. Officer |
| Mr. Ming Fai Chung CPA | Company Sec. |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2234 |
| Price-to-Sales TTM: | 51.7458 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 315 |